Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis

Nov 19 2018

• By Michael Cipriano and Nielsen Hobbs

Sparks

Related Content

Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says

Nov 02 2018

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

Nov 02 2018

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Oct 01 2018

Alkermes' Depression Drug Likely Needs Another Trial After Crushing US Advisory Cmte. Vote

Nov 02 2018

Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review

Nov 19 2018

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

May 15 2018

Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic

Jun 15 2018

Related Companies

Tonix Pharmaceuticals Holding Corp.

Sage Therapeutics, Inc.

Alkermes plc

UroGen Pharma, Ltd.

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Eiger BioPharmaceuticals, Inc.

Replicor Inc.

Novartis AG

Additional Topics

United States Review Pathway Drug Review Regulation BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window